Accepted Manuscript

Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials

Michael E. Trautmann, Luc Van Gaal, Jenny Han, Elise Hardy


PII: S1056-8727(17)30035-1

DOI: doi: 10.1016/j.jdiacomp.2017.06.004

Reference: JDC 7042

To appear in: Journal of Diabetes and Its Complications

Received date: 10 January 2017 Revised date: 31 March 2017 Accepted date: 8 June 2017



Please cite this article as: Trautmann, M.E., Van Gaal, L., Han, J. & Hardy, E., Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials, *Journal of Diabetes and Its Complications* (2017), doi: 10.1016/j.jdiacomp.2017.06.004

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials

Michael E. Trautmann^{a,*}, Luc Van Gaal^b, Jenny Han^c, Elise Hardy^d

^a Diabetes Research, Fueerbarg 16a, D-22393, Hamburg, Germany

^b Antwerp University Hospital, Antwerp, Belgium

^c Pharmapace, 10509 Vista Sorrento Parkway, Suite 303, San Diego, CA, USA 92121

^d AstraZeneca, Gaithersburg, MD, USA

* Corresponding author at: Diabetes Research, Fueerbarg 16a, D-22393 Hamburg, Germany.

Tel.: +49 40 60097132; fax: +49 40 60097135.

E-mail address: michael@trautmann-diabetes.com (M.E. Trautmann).

Running Head: Long-term use of exenatide once weekly in type 2 diabetes

Download English Version:

https://daneshyari.com/en/article/5588069

Download Persian Version:

https://daneshyari.com/article/5588069

<u>Daneshyari.com</u>